𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nongenomic actions of the steroid hormone 1α25-dihydroxyvitamin D3

✍ Scribed by Daniel T. Baran

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
413 KB
Volume
56
Category
Article
ISSN
0730-2312

No coin nor oath required. For personal study only.

✦ Synopsis

Recent studies indicate that the vitamin D hormone, 1 a,25-dihydroxyvitamin D3 exerts rapid effects (seconds to minutes) in a variety of cell types. These rapid nongenomic actions in osteoblasts include effects on membrane voltage-gated calcium channels, phospholipase C activity, and the sodium/hydrogen antiport. Since the rapid effects occur in osteoblasts that lack the nuclear vitamin D receptor, it is postulated that the nongenomic responses to the hormone reflect interaction with a separate, membrane localized signalling system. Preliminary studies demonstrate the presence of a receptor on the membranes of osteoblasts that lack the nuclear vitamin D receptor. This membrane receptor recognizes la,25-dihydroxyvitamin D3 and its inaction 1 P epimer, but not 25-hydroxyvitamin D3.

These rapid nongenomic actions generated by interaction with the membrane receptor modulate the effects of the hormone on gene transcription. Thus, the rapid nongenomic pathway may play a regulatory function in modulating the genomic pathways affected by la,25-dihydroxyvitamin D3.

📜 SIMILAR VOLUMES

1α,25-Dihydroxyvitamin D3-3β-bromoacetat
1α,25-Dihydroxyvitamin D3-3β-bromoacetate, an Affinity-Labeling Analog of 1α,25-Dihydroxyvitamin D3 Receptor
✍ R. Ray; S. Ray; M.F. Holick 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 373 KB

In this communication we describe the synthesis of \(1 \alpha, 25\)-dihydroxyvitamin \(\mathrm{D}_{3}\) - \(3 \beta\)-bromoacetate \(\left[1,25(\mathrm{OH})_{2}-\mathrm{BE}\right]\), an analog of \(1 \alpha, 25\)-dihydroxyvitamin \(\mathrm{D}_{3}\left[1,25(\mathrm{OH})_{2} \mathrm{D}_{3}\right]\), a

Annexin II is the membrane receptor that
Annexin II is the membrane receptor that mediates the rapid actions of 1α,25-dihydroxyvitamin D3
✍ Daniel T. Baran; John M. Quail; Rahul Ray; John Leszyk; Thomas Honeyman 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 404 KB 👁 1 views

1␣,25-Dihydroxyvitamin D 3 has been shown to exert its effects by both genomic (minutes to hours) and rapid (seconds to minutes) mechanisms. The genomic effects are mediated by interaction with the nuclear vitamin D receptor. We show that the vitamin D analog, [ 14 C]-1␣,25-dihydroxyvitamin D 3 brom

1α,25-Dihydroxy-3-Epi-vitamin D3, a natu
1α,25-Dihydroxy-3-Epi-vitamin D3, a natural metabolite of 1α,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion
✍ A.J. Brown; C. Ritter; E. Slatopolsky; K.R. Muralidharan; W.H. Okamura; G.S. Red 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 1 views

1␣,25(OH) 2 D 3 is an important negative regulator of parathyroid hormone (PTH) gene transcription. In parathyroid cells, as in other target tissues, 1␣,25(OH) 2 D 3 is degraded by side chain oxidation by the inducible 24-hydroxylase. We have previously shown that one metabolite of this pathway, 1␣,

Analogs of 1α,25-dihydroxyvitamin D3 as
Analogs of 1α,25-dihydroxyvitamin D3 as pluripotent immunomodulators
✍ Evelyne van Etten; Brigitte Decallonne; Lieve Verlinden; Annemieke Verstuyf; Rog 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

## Abstract The active form of vitamin D~3~, 1,25(OH)~2~D~3~, is known, besides its classical effects on calcium and bone, for its pronounced immunomodulatory effects that are exerted both on the antigen‐presenting cell level as well as directly on the T lymphocyte level. In animal models, these im